All In Biotech

Drug Trial Radar · NCT07873827

KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies

A Phase 1/2, Open-label, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy of MEN2312 (KAT6 Inhibitor) in Participants With Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 115 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

115

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

May 12, 2028

Study completion May 12, 2030

Sponsor

Lead sponsor
Stemline Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.

Conditions

  • Hematological Malignancy

Interventions

  • MEN2312Drug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: Cycle 1 (28 days)
  2. Part A: Number of Participants Experiencing Severe ToxicityTime frame: Cycle 1 Day 1 through the completion of Cycle 4 (each cycle length = 28 days) (maximum duration: 112 days)
  3. Part B: Overall Response Rate (ORR) per Central Laboratory AssessmentTime frame: Up to approximately 1.5 years
  4. Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 1.5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.